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Abstract
Background: Heart failure (HF) patients show high morbidity and mortality rate with increased risk of malignant arrhythmia
and thromboembolism. Anticoagulation reduces embolic event and death rates in HF patients with atrial fibrillation, but if
antithrombotic therapy is beneficial in patients with HF in sinus rhythm is still debated.
Methodology and Principal Findings: We conducted a systematic review of prospective, randomized controlled trials
(RCTs) to assess the efficacy and safety of oral anticoagulant therapies (OATs) compared to antiplatelet treatment in HF
patients in sinus rhythm. MEDLINE, Web of Science, CENTRAL and Scopus databases were searched up to May 2012. Four
RCTs were identified and a total of 3663 patients were included in the meta-analysis. Patients with both ischemic and non-
ischemic HF were included. There was no significant difference in mortality (odds ratio (OR) 1.01, 95% confidence interval
(CI) 0.86 to 1.19) between OATs group and antiplatelet drug group. OATs have reduced ischemic stroke risk (OR 0.49, 95% CI
0.32 to 0.74), but have increased major bleeding risk (OR 2.01, 95% CI 1.40 to 2.88) compared to antiplatelet treatment.
Conclusion: In HF patients in sinus rhythm OATs do not show a better risk-benefit profile compared to antiplatelet
treatment in cardioembolism prevention. Warfarin and aspirin seem to be similar in reducing mortality. Warfarin reduces the
incidence of ischemic stroke, but increases major bleedings. Thus, it is possible to speculate that aspirin prescription be
indicated in patients with high risk of bleeding, whereas warfarin could be preferred in patients with high thromboembolic
risk.
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Introduction
Heart failure (HF) is a growing public health problem worldwide,
and it is associated with an increased risk of left ventricular thrombus
formation and cerebral embolism due to endothelial dysfunction,
reduced blood flow andunderlying state of hypercoagulability [1–4].
In thepopulation-basedFraminghamHeartStudy, therelative riskof
stroke in individuals withHF compared to those without HFwas 4.1
formen and2.8 forwomen [5]. The risk of cardioembolism is further
enhanced by the presence of atrial fibrillation (AF), however HF
patients in sinus rhythm still have higher thromboembolic risk. A
retrospective analyses reports a yearly incidence of thromboembo-
lismof1.0%–4.5%inHFpatientswithoutAF[6]. In theSAVEstudy,
an observational analysis of 2231 patients with left ventricular
dysfunction after acute myocardial infarction, 4.6% of patients had
fatalornonfatal strokesduringthestudyperiod (rateof strokeperyear
of follow-up, 1.5 percent) and the estimated five-year stroke rate was
8.1 percent in the entire population [7,8]. Antiplatelet therapy is
commonly prescribed in HF patients in sinus rhythm since ischemic
cardiomyopathy is theprincipalunderlyingcause [9,10].Conversely,
oral anticoagulant therapy (OAT), that includes oral vitamin K
antagonists (VKAs) and new oral anticoagulant therapies, is
commonly prescribed inHFpatientswithAF since it has been shown
more efficacious than aspirin in reducing embolic risk [9,11].
International guidelines recommend the use of VKAs inHF patients
withAFtoprevent cardioembolic riskbutOATisnot indicated inHF
patients without AF [12,13,14].
The aim of the present meta-analysis has been to assess the
efficacy and safety of OAT in comparison to antiplatelet treatment
in HF patients in sinus rhythm.
Methods
The study was designed according to the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
statement [15].
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Search Strategy
MEDLINE, Web of Science, Cochrane CENTRAL, Scopus
databases were searched for articles in all languages published
until May 2012. Gray literature was not considered as a priority
asset of our systematic review. Studies were identified and
evaluated by the authors (GR, GP, AS) using the major medical
subject heading combined with text and key words. As example for
MEDLINE (‘‘heart failure’’[MeSH Terms] OR ‘‘heart failure’’[All
Fields] OR (‘‘heart’’[All Fields] AND ‘‘failure’’[All Fields])) AND
(‘‘anticoagulants’’[MeSH Terms] OR ‘‘anticoagulants’’[All Fields]
OR (‘‘anti’’[All Fields] AND ‘‘coagulant’’[All Fields]) OR ‘‘anti
coagulant’’[All Fields] OR ‘‘warfarin’’[MeSH Terms] OR ‘‘war-
farin’’[All Fields] OR ‘‘antithrombins’’[MeSH Terms] OR
‘‘antithrombins’’[All Fields] OR ‘‘antithrombin’’[All Fields] OR
‘‘aspirin’’[MeSH Terms] OR ‘‘aspirin’’[All Fields]). Additional
eligible studies were identified screening the reference lists of
studies included in our analysis.
Study Selection
All selected titles and abstracts were independently reviewed by
two authors (GP,GR). Studies were excluded if the title and/or
abstract were not appropriate for the aim of our review. Full texts
were subsequently obtained for eligible studies or when the
relevance of an article could not be certainty excluded. Disagree-
ment was resolved by consensus and by opinion of a third reviewer
(AS), when necessary. Selected studies were eligible if they met the
following criteria: patients with heart failure due to any underlying
cause without AF; adults only; patients treated with OAT or
antiplatelet treatment; at least 100 patients enrolled; duration of
treatment at least 1 month; RCT design. Reviews, case-reports,
non-human studies and abstracts or conference proceedings were
excluded. In summary, the present meta-analysis included only
RCTs that compared the efficacy and the safety of OAT versus
antiplatelet treatment among HF patients in sinus rhythm.
Risk of Bias in Included Studies
Using the guidelines in the Cochrane Handbook for assessment
of risk of bias (RoB), RCTs were graded by two independent
reviewers (GR and GP) basing on sequence generation, allocation
concealment, incomplete outcome data, selective outcome report-
ing, blinding of participants and personnel and blinding of
outcome assessment [16]. These items were considered as key
domains for RoB assessment and classified as ‘‘adequate’’ (low risk
of bias), ‘‘inadequate’’ (high risk of bias), or ‘‘unclear’’. Studies with
adequate procedures in all domains were considered to have a low
risk of bias; ones with inadequate procedures in one or more key
domain(s) were considered to have a high risk of bias; and ones
with unclear procedures in one or more key domain(s) were
considered to have an unclear risk of bias. Disagreement was
resolved by consensus and by opinion of a third reviewer (AS).
Data Extraction and Types of Outcomes Measures
Data extraction has been completed by two reviewers (GR, GP)
independently using a standardized form. Disagreement was
resolved by consensus and by the opinion of a third reviewer
(LM), when necessary. Overall mortality was the primary out-
come. Additional efficacy outcomes were: ischemic stroke,
myocardial infarction (MI), hospital admission. Main safety
outcomes were: major bleedings and intracerebral bleedings. A
separated analysis was planned for HF patients with ischemic
cardiomyopathy and with non-ischemic cardiomyopathy. To
define the severity of bleeding events we planned to use the
International Society of Thrombosis and Haemostasis (ISTH)
classification [17].
Statistical Analysis
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated. The results were pooled using the inverse variance
method. The random effect model described by DerSimonian and
Laird [18] was used to synthesize data rather than the fixed effect
model because it incorporates intra- and inter-study variability.
The software Review Manager (RevMan, version 5.1.4 for
Windows 7, Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2011) supported the analysis.
Assessment of Heterogeneity and Publication Bias
Heterogeneity was assessed using I2 statistic that accounts of
between-study (or inter-study) variability as opposed to within-
study (or intra-study) variability. Because of latent clinical
heterogeneity, random-effects model was used, independently of
statistical evidence for heterogeneity. Heterogeneity has been
considered substantial if I2 value was greater than 25% [19]. If
substantial heterogeneity was identified, subgroup analyses and
sensitivity analyses were performed. Presence of publication bias
was explored performing the test for asymmetry of the funnel plot
by Egger that is a linear regression of normalized effect estimate
(estimate divided by its standard error) against precision (reciprocal
of the standard error of the estimate) [20,21].
Results
Of 17625 articles identified by the initial search, 16 were
retrieved for more detailed evaluation and 4 were finally included
in the meta-analysis (Figure 1) [22–25]. All included studies have
enrolled patients without atrial fibrillation However, we found
three studies not reporting separated data for patients in sinus
rhythm and in atrial fibrillation, thus they were excluded from
meta-analysis [26–28]. Baseline characteristics of patients included
in the studies were summarized in Table 1. Studies population
sizes ranged from 180 [22] to 2305 [25] patients, for a total of
3663 included patients. Quality assessment items have been
summarized in Figure 2. The WASH study [22], the pilot study of
WATCH study, included 279 patients that were randomized to
warfarin (target INR 2.5), aspirin (325 mg), or placebo and
followed up for a mean of 27 months. The HELAS trial [23]
separated 197 patients according to the etiology of their HF. Only
patients in the ischemic cardiomyopathy group (n.115) were
randomized to receive warfarin (target INR 2–3) or aspirin
(325 mg), while patients in the non-ischemic group (n.82) were
randomized to receive warfarin or placebo. Patients were followed
up for a mean period of 20 months. We included in our meta-
analysis only the ischemic group since it compared warfarin versus
aspirin. The WATCH trial [24] included 1587 HF patients
receiving aspirin (162 mg), clopidogrel (75 mg), or warfarin (target
INR 2-3.5), followed up for a mean duration of 21 months. The
WARCEF trial [25] randomized 2305 HF patients to receive
aspirin (325 mg) or warfarin (target INR 2.5–3.5), with a mean
follow up of 42 months.
Efficacy Outcomes
In the cumulative analysis of all patients (n = 3663), mortality
rate was not significantly different between warfarin and aspirin
groups (OR 1.01, 95% CI 0,86 to 1,19; I2 = 0%). Warfarin was
associated with a significant reduction of ischemic stroke
compared to aspirin (OR 0.49, 95% CI 0.32 to 0.74; I2 = 0%,
NNT=50). Hospital admission and MI rates were not significantly
Warfarin vs Aspirin in HF: A Meta-Analysis
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different between warfarin and aspirin groups (OR 0.80, 95% CI
0.49 to 1.30, I2 = 80% and OR 1.00, 95% CI 0.59 to 1.68;
I2 = 25% respectively) (Figure 3). One study removed analysis
showed that, only when the WARCEF study was excluded from
analysis, there was a reduced hospital admission rate in OAT
compared to aspirin group with a statistically significant reduction
in heterogeneity (OR=0.65, C.I. 0.50 to 0.85; I2 = 0%,
NNT=15). Subgroup analyses in ischemic and non ischemic
patients were not performed since only one study provided
separated data for HF etiology [23].
Safety Outcomes
Data about bleeding events were not reported in enough trials
for applying ISTH classification and the definition of major
bleeding provided by authors was used. In the overall cohort of
patients (n = 3663), OAT was associated with significant increase
in major bleeding events compared to aspirin (OR 2.01, 95% CI
1.39 to 2.89; I2 = 4%, NNH=35). Moreover, a trend to increase
in intracerebral bleedings has been observed in the warfarin
group, but it was not statistically significant (OR 2.18, 95% CI
0.75 to 6.30; I2 = 0%).
Publication Bias
No publication bias was detected by Egger’s linear regression
method for each single outcomes analysis although the limited
number of studies could not rule out a possible publication bias
(data not shown).
Discussion
In the medical community there is not general consensus in
either recommending or advising against OAT in HF. Several
evidence have recommended OAT in HF patients with AF, as
prevention for the high cardioembolic risk observed in this
population. Differently, the majority of HF patients due to
ischemic etiology takes aspirin for secondary prevention of
coronary heart disease. Therefore, the aim of this present meta-
analysis has been to assess potential differences in efficacy and
safety between these two therapeutic modalities in HF patients in
sinus rhythm. Our results indicate that warfarin does not show
a better efficacy-safety profile compared to aspirin in preventing
cardioembolism in HF patients without AF. However, when
compared to aspirin, warfarin was associated with a significant
reduction (OR 0.49) of ischemic stroke incidence with a relative
risk reduction that is comparable to that reported in HF patients
with AF treated with OAT [29]. Nevertheless, due to the low
annual stroke rate observed in HF patients in sinus rhythm
(between 0.8% and 3.2% per year), the advantages deriving from
routine anticoagulation cannot overcome the increased risk of
bleedings related to warfarin use [24,30–33]. Consistently, our
data show that OAT was associated with a more than doubled
bleeding risk, with a trend to increase also the risk of intracerebral
bleedings. It is important to underline, that only in the HELAS
study, HF patients were dived for ischemic or non ischemic
cardiomyopathy, thus no conclusions can be drown about efficacy
or safety in these different patient subpopulations.
Figure 1. Meta-analysis flow chart.
doi:10.1371/journal.pone.0052952.g001
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In HF patients with non ischemic etiology and without AF, no
studies are available about efficacy and safety of OAT or
antiplatelet therapy compared to placebo, whereas several line of
evidence support the use of aspirin in HF patients due to ischemic
etiology as secondary prevention of coronary artery disease. Thus,
RCTs comparing aspirin vs. placebo in HF patients in sinus
rhythm and non ischemic etiology might be helpful to guide
therapy in this specific HF subpopulation. In the present analysis
the hospital admission rate for worsening HF was lower in
warfarin group only after exclusion of WARCEF study. Its
exclusion reduces the heterogeneity among studies but unfairly
reduces the available information since this is the largest trial with
the longest follow-up. The important issue regarding discordant
results on the incidence of hospital admissions for worsening HF in
patients treated with warfarin or aspirin is not addressable.
Unfortunately, despite it would be of great interest whether
warfarin treatment impacts quality of life (especially in terms of
anxiety burden related to OAT monitoring), the identified trials
did not investigate this relevant aspect which certainly would be an
important argument for future trial investigations.
Strengths and Limitations of this Meta-analysis
The main strengths of our review include the systematic strategy
and the high score at Cochrane quality assessment for all trials
included. Our meta-analysis has one major shortcoming. It was
not carried out on individual patients data exploring subgroups
with higher thromboembolic risk. Moreover, there are some
limitations in the outcome evaluation due to the too small sample
size and the too short follow up (i.e. 2 years) period, resulting in
a low number of events in the trials included. The exclusion of
gray literature could be a limitation of our search strategy. It is
important to underline that in WATCH trial, aspirin dosage is
lower than that used in the other trials, thus explaining the lower
efficacy of treatment reported. Although differences in trial
definitions of outcomes among different trials should be considered
for the interpretation of the overall result, it is important to
mention that mortality and ischemic stroke, the principal efficacy
outcomes evaluated in our study, are hard endpoint not affected
by study definitions. The absence of heterogeneity in the most part
of analysis supports the strength of our results. Further studies are
needed to better identify high risk HF subgroups. The definition of
an HF risk stratification score, similar to that available for ischemic
risk assessment (CHADS2 or CHA2DS2-VASc scores), or
bleeding risk assessment (HAS-BLED) [34,35], will be useful to
identify HF patients at higher risk. Finally, no evidences are
provided regarding the use of new oral anticoagulants (oral direct
thrombin inhibitors, oral Factor Xa inhibitors) which seem to offer
a different risk–benefit profile compared to warfarin and might
induce a reduction in ischemic stroke rates with less risk of major
bleeding. Thus, an head to head comparison between warfarin
and new anticoagulants (rivaroxaban, apixaban and dabigatran),
Figure 2. Risk of bias summary: review authors’ judgment
about each risk of bias item for each included study.
doi:10.1371/journal.pone.0052952.g002
Figure 3. Pooled event rate and odds risk ratio for major end point in overall cohort patients with heart failure in sinus rhythm.
doi:10.1371/journal.pone.0052952.g003
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with antiplatelet therapy might be of great interest in HF patients
in sinus rhythm.
Conclusions
In patients with HF in sinus rhythm, warfarin and aspirin seem
to be similar in reducing mortality. Warfarin reduces the incidence
of ischemic stroke, but increases major bleedings. Thus, it is
possible to speculate that aspirin could be indicated in patients
with high risk of bleeding, whereas warfarin could be preferred in
patients with high thromboembolic risk. However, further studies
are needed to clarify the role of antitrombotic therapy in HF
patients in sinus rhythm, particularly in the subpopulation with
non ischemic etiology.
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